We have recently described the association between rheumatoid arthritis and a coding single-nucleotide polymorphism in the intracellular protein tyrosine phosphatase, PTPN22. The disease-associated polymorphism, 1858 C/T (rs2476601), encodes an amino-acid change (R620W) in one of four SH3 domain binding sites in the PTPN22 molecule. We have now extended our initial studies to address three questions: (1) Is the association with rheumatoid arthritis limited to rheumatoid factor (RF) positive disease? (2) Does homozygosity for PTPN22 R620W substantially increase disease susceptibility? (3) Is there an interaction between PTPN22 and the rheumatoid arthritis (RA)-associated HLA-DRB1 shared epitope alleles? A total of 1413 Caucasian rheumatoid arthritis patients and 1401 Caucasian controls were genotyped. The results support the view that PTPN22 was strongly and preferentially associated with RF positive disease (OR ¼ 1.75, 95% CI 1.46-2.10, P ¼ 1.3 Â 10 À9 ). The PTPN22 risk allele was not significantly associated with RF negative disease (OR ¼ 1.19, 95% CI 0.92-1.53, P ¼ 0.18), although a very weak association cannot be completely excluded. There was a strong dose effect on disease risk; two copies of the PTPN22 R620W allele more than doubles the risk for RF positive RA (OR ¼ 4.57, 95% CI 2.35-8.89). There was no evidence of a genetic association between PTPN22 and HLA susceptibility alleles.
Introduction
Rheumatoid arthritis (RA) affects up to 1% of the adult population worldwide, making it the most common systemic autoimmune disease. It is two to three times more prevalent in women than in men and is characterized by immune-cell-mediated destruction of the joint architecture. Long-term prognosis is generally poor with joint destruction affecting approximately 80% of affected individuals within 20 years. [1] [2] [3] Rheumatoid factor (RF), which is an immunoglobulin directed against the Fc portion of IgG, is found in over 70% of patients with RA; high RF may confer a worse prognosis. RA patients who are RF positive tend to have more aggressive erosive bone and joint disease than those who are RF negative. 4, 5 The presence of RF may precede clinical diagnosis by many years, indicating that its production may be associated with an early key event in the autoimmune response. [6] [7] [8] [9] It is presently unclear to what extent RF positive disease differs from RF negative disease in terms of disease pathogenesis, and aside from differences in HLA associations, there are no clearly established genetic differences between the two subphenotypes of RA. In a recent case-control association study, Begovich et al 10 found a strong association of the PTPN22 1858C/T (rs2476601) single-nucleotide polymorphism (SNP) with RA. The presence of the minor 1858T allele increased the relative risk for RA almost two-fold. The carrier frequency of the 1858T risk allele in Caucasians with RA was 28% while this allele was present in approximately 17% of Caucasian controls. In this original report, the predominant association appeared to be with RF positive RA, although the number of subjects with RF negative disease was too low to reach a definitive conclusion. We have now examined this issue in a large set of both RF positive and RF negative rheumatoid arthritis patients and controls. We document that PTPN22 is specifically associated with RF positive RA, and displays a marked dose effect. Interestingly, despite the association of HLA-DRB1 with rheumatoid factor production in our RA population, there is no evidence of an association between PTPN22 and the RA associated HLA-DRB1 alleles.
Results
In order to obtain a large enough sample size for these studies, we combined RA cases from several sources, as detailed in the Methods section. Briefly, 372 patients with longstanding RA were studied from the Wichita Arthritis Center. 11 In addition, patients from two recent onset cohorts were available for study. The SONORA cohort (Study of New Onset Rheumatoid Arthritis) is comprised of 1017 patients with new onset disease who were enrolled between 2000 and 2003 for a 5-year prospective, observational study. 12 All patients were enrolled within 12 months of disease onset, and are undergoing full clinical evaluation at multiple time points, including baseline and follow-up hand X-rays. DNA and serum samples from 705 of these patients were available for study. A second longitudinal cohort, being followed in the National Data Bank for Rheumatic Diseases (NBD), has enrolled new onset RA patients within 6 months of diagnosis; 13 336 patients from this cohort were chosen for study on the basis of having been followed for 4 years. From these three resources we assembled 1413 RA patients, of whom 968 (68.5%) were RF positive on at least one occasion, and 445 were RF negative. In the SONORA cohort, serological measurements of RF were available at baseline and 1 year. Patients seen at the Wichita Arthritis Center generally had multiple serological assays carried out over many years. Patients in the NDB inception cohort were tested only at the time of enrollment.
Genotyping data from all Caucasian RA patients in the three sample sets were combined for analysis (n ¼ 1413) ( ). For the allele frequency comparison, the 1858T allele frequency was significantly increased at 14.36% in the RF positive subgroup compared with the control T allele frequency of 8.
, OR ¼ 1.75, 95% CI 1.46-2.10). The risk allele frequency of the RF negative subgroup (10.22%) was not different from that of the normal controls (P ¼ 0.18), but it was significantly different when compared to the RF positive subgroup (P ¼ 2.4 Â 10 À3 , OR 1.47, 95% CI 1.15-1.89).
In addition to the specific association of PTPN22 R620W with RF positive disease, there was strong evidence for a dose effect in the RF positive subgroup. As shown in Table 1 , when comparing the risk profiles of the CT and the TT genotypes, the TT genotype carries approximately a three-fold risk for RF positive disease, compared with the CT genotype, with OR ¼ 4.57 and 1.53, respectively. Compared with controls, this increase in risk of the TT genotype was highly significant (P ¼ 9.8 Â 10
À7
). Finally, we searched for evidence of association between PTPN22 and HLA-SE genotypes within the group of RF positive patients. Both HLA DR typing and PTPN22 data were available on 658 subjects. Table 2 shows the distribution of PTPN22 genotypes among the various HLA subgroups according to the number of shared epitopes, and also stratified by the presence of the (Table 2 and data not shown).
Discussion
We previously reported the strong association of the 1858C/T PTPN22 missense SNP with RA 10 . Herein, we confirm and expand those findings in a combined sample derived from three large independent Caucasian RA sample sets. We have further stratified our RA population by RF production and the presence of SE alleles. A statistically significant association of the PTPN22 risk allele is observed exclusively within the RF positive subgroup; minimal, if any, evidence for association was found in patients with RF negative disease. It is possible that the OR 41 in the RF negative group may reflect a very weak association of the PTPN22 R620W allele with this disease subset. However, it seems likely that misclassification of RF positive patients into this group is a better explanation for this finding, since only one or two RF measurements were carried out for the majority of the patients under study.
The predominant association of PTPN22 R620W with RF positive RA is of considerable interest in light of the phenotype that is observed in the PEP knockout mouse (PEP is the murine homolog of human PTPN22). Hasegawa et al 14 showed that T cells from PEP knockout mice had lowered thresholds for TCR signaling and increased numbers of effector and memory T cells. In addition, these knockout mice showed evidence of increased number of germinal centers (GC) and increased immunoglobulin levels. These abnormalities in the humoral immune system appear to reflect the role of T cells in regulating B cell differentiation, since changes in B cell function were sought, but not observed in these mice. Thus, although a direct role for PTPN22 in B cell signaling is possible, the abnormal production of GC in this model is ascribed to a T cell defect. Notably, autoantibodies were not observed in these knockout mice. However, the genetic background in which these experiments were performed (B6) is not associated with autoimmunity.
The association of PTPN22 R620W with the production of RF in RA is consistent with the fact that other autoimmune diseases that have a prominent humoral component also show an association with this polymorphism. Both type 1 diabetes 15 and systemic lupus erythematosus 16 have been reported to associate with the PTPN22 W620 allele with similar levels of risk, and the data in SLE support a dosage effect similar to what we have observed in RA. 16 In addition, we have recently shown an association with autoimmune thyroid disease (Criswell et al, manuscript in preparation). Strikingly, in all of these disorders, the appearance of autoantibodies can precede the development of overt clinical disease by months or years. [17] [18] [19] Thus, it will be of considerable interest to investigate whether PTPN22 is primarily associated with the early development of these autoantibodies, or, alternatively whether the PTPN22 risk allele influences the progression to overt autoimmune disease once autoantibodies have developed. Of course, these possibilities are not mutually exclusive.
The formation of ectopic GC has been reported in both RA and autoimmune thyroiditis, as well as several other autoimmune diseases. 20 Excessive GC formation has also been observed in autoimmune mouse strains that exhibit type 1 diabetes and lupus-like disease. 21 In the case of RA, the presence of GC within the inflamed synovium is not the most common phenotype, but it is present in a significant minority of patients, and is accompanied by distinct patterns of cytokine and chemokine expression. 22 Rheumatoid factor is produced locally by B cells within the inflamed synovium, and sequence analysis of these immunoglobulins can show evidence of somatic mutation 23, 24 4 Evidence of such somatic mutation is consistent with the T cell dependent B cell differentiation that typically occurs within GC. It is not entirely clear whether the variability of synovial pathology reflects meaningful disease subsets or different stages of disease, or both. Detailed information on synovial histology is not available for analysis in large populations of patients. However, it will clearly be of great interest to examine whether the PTPN22 genotype correlates with these phenotypes, and particularly whether homozygosity for the R620W allele is associated with the more prominent appearance of ectopic GC within the rheumatoid synovium. Since CD8 þ CD40L þ T cells have been implicated in the maintenance of these structures, 25 a specific role for PTPN22 in the regulation of these T cells should be explored in this context.
In the setting of rheumatoid arthritis, RF production is thought to be dependent, at least in part, on MHC class II restricted CD4 þ T cell responses. 3 RA associated HLA-DR alleles bearing the shared epitope, particularly DRB1*0401 and 0404, are positively associated with RF production in patients with RA. This is also the case in our data set (data not shown). However, HLA-DRB1 shared epitope alleles are neither sufficient nor required for RF production. Certain environmental factors, such as smoking, are also associated with RF production in RA, and appear to interact with HLA-DR. 26 Nevertheless, our results indicate that the PTPN22 R620W polymorphism is an independent risk factor for RF positive RA, and there is no convincing evidence for an association with HLA SE alleles in this data set.
We have shown that homozygosity for the PTPN22 risk allele dramatically increases susceptibility to RF positive disease, and similar findings have been noted in systemic lupus 16 and are suggested by the published data on type 1 diabetes. 15 This implies that the negative regulatory effect of PTPN22 is dose-dependent, consistent with a threshold effect on TCR signaling. Others and we have shown that R620W polymorphism reduces binding of PTPN22 to the intracellular tyrosine kinase, Csk, by altering the proximal SH3 binding site in the PTPN22 molecule. 10, 15 However, an alteration of T cell function by the R620W allele has not yet been directly demonstrated in humans. The evidence of a dose effect for disease susceptibility suggests that in vitro functional studies will be more fruitful if they are carried out in homozygous individuals, in whom a relatively subtle change in TCR signaling thresholds may be more easily detected.
In summary, our results from three independent Caucasian RA populations reaffirm our initial findings of an association of the PTPN22 R620W polymorphism with RA. In addition, we have shown that the predominant association is with RF positive, but not RF negative, disease. There is a marked dosage effect when comparing the CT and TT risk genotypes, and there is no association between HLA SE status and PTPN22 R620W. Further investigations are needed to identify the potential role of PTPN22 in other clinical manifestations of RA. Longitudinal outcome data from the SONORA study should be particularly useful in this regard with respect to disease progression as well the response to specific biologic therapies. Study (N ¼ 823) . These RA sample sets were combined and only Caucasian patients were subsequently used in the analysis. Patient samples obtained from the Wichita Rheumatic Disease Data Bank were representative of Caucasian patients followed in a rheumatology practice since 1974. Mean disease duration was greater than 10 years and mean age of onset of 45 years, 83% of this cohort were RF positive over several time points. Patient samples used in conjunction with the NDB Inception Cohort of Rheumatoid Arthritis Patients were collected as previously described were also included in this cohort. 13 Enrollment of patients occurred within 6 months of clinical diagnosis. The mean age of this cohort was 54 years old, 65% were RF positive at time of enrollment.
Patient samples obtained from The SONORA Study were from Caucasian patients meeting the ACR criteria and enrolled within 3-12 months of diagnosis. The mean age of onset was 52 years and 64% were RF titer positive either at study enrollment or at 1-year follow-up. 
RF determination

Genotyping
After receiving informed consent, DNA was isolated by standard methodologies from peripheral whole-blood samples. Genotyping of the PTPN22 SNP (rs2476601, 1858C-T, R620W) was performed using a PSQ HS 96A Pyrosequencer. Briefly, 2 ng of DNA was amplified by PCR in a 10 ml reaction using the following primers: forward 5 0 -GTTGCGCAGGCTAGTCTTGA-3 0 , reverse 5 0 -GCT GCT CCG GTT CAT AGA TT GGATAG-CAACTGCTCCAAGG-3 0 , Univ1_B 5 0 -Biotin-GCT GCT CCG GTT CAT AGA TT-3 0 . The addition specific sequences to the 5 0 end of the reverse primer (shown in italics) allowed the use of a biotinylated universal primer Univ1_B. These primers were used at a ratio of 1 : 9 (reverse : universal primer). PCR conditions were as follows: 951C -12 min, 50 Â (951C -45 s, 56.41C -45 s, 721C -45 s), 721C -10 min, 41C forever. The amplicon was denatured with NaOH, separated, washed and neutralized.
The sequencing primer 5 0 AAATGATTCAGGTGTCC3 0 was used in combination with appropriate pyrosequencing substrates and enzymes according to the manufacturer's instructions to detect the polymorphism.
HLA typing was performed as previously described. 29 
Statistical analysis
All 2-by-2 contingency tables are analyzed by the Pearson's w 2 test. The statistical program used is S-PLUS version 3.4 (MathSoft, Inc.), and the subroutine chisq.test was applied. Fisher's exact test led to similar results (R version 1.8.0, subroutine fisher.test), thus these were not shown here. The formula for the 95% confidence interval for the odds ratio (OR) is due to Woolf. 30 
